Glasgow diagnostics company has appointed Dr David Eustace as operations director to help drive its product development and laboratory operations.
The company appointed Dr Eustace following a period of growth, which saw it develop blood tests for early detection of cancer.
Dr Eustace joins from Bruker Daltonics, the American-owned scientific instruments and diagnostics company, where he worked as operations director in Germany and Scotland.
He has more than 13 years of experience in the industry, working for Renishaw Diagnostics, Bruker Molecular Testing and most recently the Bruker Covid-19 response projects at its plant in Germany.
Dxcover, is a spin-out from the University of Strathclyde, and is aiming to be a world leader in liquid biopsy and artificial intelligence for early detection of cancer and other diseases.
The company formerly ClinSpec Diagnostics rebranded earlier this month as it revealed its plans for further growth.
Since it emerged from the university in 2019, the company has raised £5.1m in funding to progress its multi-cancer development program.
Dxcover completed its second clinical study this year, showcasing the clinical utility of its brain cancer test.
Dr Eustace, newly appointed operations director at Dxcover, commented: “Earlier cancer diagnoses result in significantly higher survival rates and the Dxcover team has been making huge steps to translate groundbreaking technology into the clinic to make that possible”.
Chief executive Mark Hegarty, said: “The appointment of David marks a significant step in the growth of the Dxcover business and we are thrilled to attract such a high calibre professional and industry leader to our growing team.”
Don’t miss the latest headlines with our twice-daily newsletter – sign up here for free .